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Objective: Using ultrasonography (US) to guide botulinum toxin type A (BTX-A) injection
in patients with post-stroke wrist and finger flexor muscle spasticity and assessing clinical
outcomes after the injection and rehabilitation intervention.
Methods: Twenty-three patients with wrist and finger spasticity after stroke were
recruited in this study from May 2012 to May 2013. Under US guidance, the proper
dose (250 U) of BTX-A was injected into each spastic muscle at two injection sites. Then,
conventional rehabilitation training started next day after BTX-A injection. The degree of
spasticity was assessed by modified Ashworth scale (MAS) and wrist and finger motor
function by active rang of movement (AROM), and Fugl-Meyer assessment (FMA) at the
baseline, 1, 2, 4 and 12 weeks after BTX-A injection.
Results: Significant decreases (p < 0.02) in the MAS scores of both the finger flexor
muscle tone and wrist flexor muscle tone measured at 1, 2, 4, and 12 weeks after the
BTX-A injection were found in comparison with the baseline scores. Compared with the
baseline, the AROM values of the wrist and finger extensions and the FMA scores of the
wrist and hand significantly increased (p < 0.02) at 2, 4 and 12 weeks after the BTX-A
injection.
Conclusions: US-guided BTX-A injection combined with rehabilitation exercise decrease
spasticity of the wrist and finger flexor muscles and improve their motor function in stroke
patients up to 12 weeks following BTX-A injection.
Keywords: muscle spasticity, ultrasonography guidance, intramuscular injection, botulinum toxin type A, post-
stroke rehabilitation
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Introduction
Spasticity is a major cause of motor control deficits post stroke.
Approximately one-third of stroke patients develop muscle
spasticity and these patients often require specific treatment. It
has been reported that upper extremity hypertonia (Ashworth
score >1) occurs in 63% of patients with initial paralysis during
the first 26 weeks post-stroke (Van Kuijk et al., 2007). Long-
term spasticity can lead to a seriesof complications, including
secondary muscle atrophy and joint deformity. Moreover, the
spastic posture and deformity of the affected limbs often cause
particular function impairment. For example, frequent flexor
spasticity of the upper limb commonly impairs motor function
of the hand, especially when the patient intends to open
the hand and grasp an object. Patients with a functionless
rigid hand have to face many daily living problems such as
personal hygiene, eating and dressing. As a result, their quality
of life is greatly decreased. One of major goals for post-
stroke treatment is to reduce spasticity for improved motor
function.
Botulinum toxin type A (BTX-A) causes a neuromuscular
block in acetylcholine release and can prevent neuromuscular
transmission and muscle contraction. BTX-A is regarded as an
effective treatment agent, and the efficacy and safety of BTX-A
injected in post-stroke patients with lower limb spasticity have
been suggested in few limited-scale randomized-controlled trials
(Mancini et al., 2005; Farina et al., 2008) and in a meta-analysis
study (Rosales and Chua-Yap, 2008).
However, a successful and safe therapy with BTX-A requires
anatomically accurate administration of BTX-A into the muscle
belly, as it is well known that BTX-A can cause negative
effects on the adjacent normal muscles. Knowing the location
of the needle can help clinicians more accurately inject BTX-
A into the target muscle. So far, manual needle placement
(MNP), electromyography (EMG), electrical stimulation (ES),
and ultrasonography (US; Schroeder et al., 2006) have all been
applied to guiding BTX-A injection. According to the European
consensus for the use of BTX-A in adult spasticity (Wissel et al.,
2009), these techniques can aid muscle localization; however,
the consensus does not provide recommendations of the most
suitable techniques for aiding identification of target muscles for
BTX-A injection. Furthermore, no detailed procedures for the
accurate placement of the needle using US imaging has yet been
provided. Therefore, additional studies are needed to clarify these
issues.
US is a well-established reliable and reproducible imaging
method for definingmuscle anatomy. An ultrasound systemwith
a 7.5 MHz linear transducer can provide sufficient resolution
for both superficial and deep-seated muscles (Willenborg et al.,
2002). As an alternative to electrophysiological techniques, US
offers a visually controlled injection of BTX-A (Berweck et al.,
2002, 2004). A study comparing MNP, ES, and US-guidance
for BTX-A injection into the gastrocnemius of adults with
spastic equinus after stroke indicated that themodified Ashworth
scale (MAS) score was improved more in the US and ES
groups than in the MNP group, while the ankle passive range
of motion (PROM) had a greater increase in the US group
than in the ES and MNP groups (Picelli et al., 2012). In
China, physicians in Physical Medicine and Rehabilitation have
limited training using electrophysiological techniques and thus
do not widely apply ES guidance to administration of BTX-A
injection.
Given that accurately injecting BTX-A into the right location
of the target muscle is vitally important for effectively treating
spasticity with this approach, the current study aimed at using
sonographic imaging to guide BTX-A injection in patients with
post-stroke wrist and finger spasticity and to assess the follow-
up motor function outcomes. The results of the study provide
useful information related to helping make accurate focal BTX-A
injection in clinical practice.
Materials and Methods
Subjects
Post-stroke patients treated in the Department of Rehabilitation
Medicine, The Third Affiliated Hospital (TAH), Sun Yat-sen
University were recruited from May 2012 to May 2013. All
participants were informed regarding the aims and contents
of the study and provided written consent to participate. The
study was approved by the Institutional Ethics Committee of the
TAH. The inclusion criteria were as follows: age >18 years; arm
spasticity as a consequence of ischemic or hemorrhagic stroke,
diagnosed by computed tomography scan or magnetic resonance
imaging; wrist and finger flexors tone graded between 1+ and
3 on the MAS; and time from stroke onset at least 3 months.
The exclusion criteria were as follows: time from stroke onset
over 1 year; contracture deformity in the upper limbs; infection
at the injection site; oral medication use such as aminoglycoside
antibiotics that can disturb the transmission of chemicals in the
neuro-muscular junction; unstable medical condition; and severe
cognitive disorders, diplegia, pregnancy, breast-feeding, history
of BTX-A treatment, and other neurological diseases.
Equipment and Medication
In this study, the injection of the needle into the target muscle
was visually guided using an ultrasound device (Voluson 730
Expert; GE Medical Systems Kretztechnik GmbH and Co. OHG,
Zipf, Austria). The frequency range of the GE M12L linear array
ultrasound probe was 9.0–13.0 MHz.
BTX-A (BOTOX, 100 units/vial; Allergen Inc., Irvine, CA,
USA) was diluted with 2 ml of 0.9% sodium chloride solution.
Ultrasound-Guided BTX-A Injection
Target Muscles and Corresponding Dosage of BTX-A
Five muscles, including the flexor carpi radialis (FCR), flexor
carpi ulnaris (FCU), flexor digitorum profundus (FDP), flexor
digitorum superficialis (FDS), and pronator teres (PT), were
selected as the target muscles in this study. The dosage of BTX-
A for each target muscle was determined according to the mass
of the target muscle and its spastic severity. Although the BTX-
A dosage differed from muscle to muscle in a given patient, the
total dosage (i.e., 250 U) used for the five muscles in each patient
was the same among all the patients.
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FIGURE 1 | Sonographic imaging of forearm muscles. (A) an image
obtained by the probe located at upper third of forearm anterior; (B) an image
obtained by the probe located at upper third of forearm medialis. FCR, flexor
carpi radialis; FCU, flexor carpi ulnaris; FDS, flexor digitorum superficialis; FDP,
flexor digitorum profundus; Pal, rum superficialis; PT, pronator teres; R, radial;
U, ulna.
Sonographic Imaging Guidance
To inject BTX-A into the FCR muscle, sonographic imaging was
performed to guide the injection. The steps of the procedure
were as follows: (1) the patient was placed in the supine
position with the elbow extended and the forearm supinated
(palm facing up). Patients who could not make or maintain
the above positions were provided with proper assistance to
achieve the needed body and arm postures; (2) the skin location
for injection into the FCR muscle was identified by using the
fingerbreadth measurement methods of Delagi et al. (2005)
and was subsequently marked; (3) the transducer was located
at the marker and positioned perpendicularly to the forearm
surface to obtain a transverse view of the FCR. By adjusting the
parameters such as view depth, focus, and gain, a clear image of
the FCRmuscle and other muscles could be displayed (Figure 1).
In the transverse (axial) view, the target muscle was scanned
from proximal to distal direction or vice versa till the largest
cross-sectional area was identified; (4) To confirm the surface
injection site, in some cases, the target muscle was stretched
passively to visualize the dynamic contracture of the muscle; and
(5) For optimal visualization of the needle point throughout the
injection, the angle between the needle and the skin was kept
approximately 30◦ (Figure 2; Picelli et al., 2014). The position
of the inserted needle was shown on real-time sonographic
images (Figure 3). Pre-injection sonographic images and the
images during the injection were collected and stored for record.
The second injection site of each target muscle was identified
by distally moving the transducer approximately 1.5–2.0 cm.
BTX-A was injected in the FCR at 2 sites, with 25 U for each
site.
Similar injection procedures were followed for the PT, FCU,
FDP, and FDSmuscles. All the BTX-A injections were performed
by the same doctor with prior experience in using US-guidance
for the injection.
Clinical Outcome Assessments for Motor
Function
The clinical outcomes of the patients’ motor function were
evaluated before the treatment of BTX-A (baseline), and 1, 2,
4 and 12 weeks after the injection by the same therapist. Three
FIGURE 2 | Sonography guidance of BTA-X injection into FCR. The
angle between the needle and the skin was approximately 30◦. The probe was
placed on the target muscles at the skin surface site.
clinical outcome measures were assessed and the procedures
were summarized below.
Modified Ashworth Scale (MAS)
The MAS scores were recorded to evaluate the degree of
spasticity. The evaluation standards refer to a grading system
scoring on a scale of 0–4 (Bohannon and Smith, 1987), where
0 is no increase in muscle tone; 1 is a slight increase in muscle
tone at the end of the range of motion; 1+ is a slight increase
in muscle tone through less than half of the range of motion; 2
is a more marked increase in muscle tone through most of the
range of motion; 3 is a considerable increase in muscle tone; and
4 means a rigid joint.
For statistical purposes, a score of 1 was considered as 1,
1+ as 2, and scores of 2, 3 and 4 were recorded as 3, 4 and 5,
respectively.
FIGURE 3 | Sonographic image indicating the inserted needle
(hyperecho between two arrows) in FCR. FCR, flexor carpi radialis; FDS,
flexor digitorum superficialis; Pal, palmaris longus; PT, pronator teres.
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Active Range of Movement (AROM)
The AROMs of the wrist and finger joints were measured
using a goniometer. To measure the AROM of the wrist, the
patients were instructed by a therapist to perform an active wrist
extension as far as possible from a flexed wrist position till the
active force produced by the extensors (agonists) was balanced
by the passive resistance from the stretched structures together
with the spastic co-contraction in the flexors (antagonists). The
AROM of the fingers was evaluated in a similar manner.
Fugl-Meyer Assessment (FMA) Scale
The FMA scale is widely accepted as a feasible and appropriate
method of assessment of motor recovery in stroke rehabilitation.
The simple FMA scale was used in this study to evaluate
motor function of the wrist and hand. Herein, 33 items
were included in the evaluation of the wrist and hand motor
function. Each item was scored on a scale of 0–2, with
higher scores indicating better motor function (Gladstone et al.,
2002). The total score ranged from 0 (hemiplegia) to 66
points (normal motor performance). The aforementioned three
assessments were performed by the same therapist who did
not know whether the patients were injected with BTX-A
or not.
Rehabilitation Training
Conventional rehabilitation training was performed 1 day after
the BTX-A injection, including joint traction, functional ES, and
active motion. Upper limb orthotics were applied to maintain the
patients’ normal joint movement for training if their condition
did not allow performance of training activities without the
orthotic assistance. The training lasted for 4 weeks with five
sessions per week and 50 min for each session. After discharge
from the hospital, the patients were asked to perform the
rehabilitation training at home and were followed up for 12
weeks after the injection. Home training was carried out three
sessions each week and 50 min each session for a total of 8
weeks. Family members were trained by a therapist to conduct
the home training with the patients. Home training activities
were recorded by the family members and were verified by
a therapist weekly. Re-assessment of MAS, AROM and FMA
at 1, 2, 4, 12 weeks after BTX-A injection was performed.
Figure 4 shows the flow diagram of the experiment in this
study.
Statistical Analysis
We conducted descriptive analyses to summarize patients’
baseline characteristics (age, gender and time from stroke
onset). All measurement data are presented as mean ±
standard deviation. The pre-treatment and follow-up clinical
evaluation scores were analyzed by nonparametric Wilcoxon
matched-pairs signed-ranks tests without assumptions on
normality of the data. Multiple comparisons (20 times) were
treated with Bonferroni Correction and the significance
level was set at p ≤ 0.05. Statistical analysis was conducted
using Stata version 14 (StataCorp LP, College Station,
TX, USA).
FIGURE 4 | Flow diagram of the experiment. MAS, modified Ashworth
scale; AROM, active range of motion; FMA, Fugl-Meyer assessment scale;
BTX-A, botulinum toxin type A.
Results
Twenty three subjects (13 males and 10 females) with wrist and
finger spasticity were recruited in this study. The mean age of
the patients was 58.2 ± 10.2 years (range, 35–70 years). The
mean duration from disease onset was 7.4 ± 2.5 months (range,
3–12 months). Fifteen and eight cases had cerebral infarction
and cerebral hemorrhage, respectively. All patients completed the
requested assessments at all five time-points (baseline and 1, 2,
4 and 12 weeks after the injection). No apparent adverse effects
were observed during the follow-up times.
MAS Assessment
All patients showed an improvement in muscle tone according
to the MAS data of the wrist and finger flexor muscles (Table 1).
Significant decreases in both the flexor digitorum muscle tone
and flexor carpi muscle tone measured at 1, 2, 4 and 12 weeks
after the BTX-A injection were found in comparison with the
baseline scores (p < 0.02). The MAS of wrist flexor muscle tone
was lowest at 2 weeks during follow-up. The MAS scores of the
wrist flexor muscle tone measured at 4 and 12 weeks tended to
be slightly increased in comparison with the score measured at 2
weeks. Different from theMAS scores of wrist flexor muscles, the
MAS score of the finger flexor muscle tone measured at 4 weeks
was lowest compared with the MAS scores measured at other
time-points (Table 1).
AROM Assessment
Although no significant improvement was found in the AROM
for wrist extension at 1 week after the injection (p = 0.29), the
AROM values were significantly increased at 2, 4, and 12 weeks
(7.0 ± 1.7◦, 11.0 ± 1.9◦, 16.0 ± 2.6◦, respectively; p < 0.02)
in comparison with the baseline (2.5 ± 1.9◦; Table 1). Similar
significant increases in the AROMvalues of finger extension were
also observed (AROM values at baseline, 2, 4, and 12 weeks:
3.1 ± 2.1◦, 6.6 ± 2.3◦, 9.8 ± 2.5◦, 13.0 ± 2.9◦; p < 0.02). The
AROM results of both the wrist and fingers showed significant
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TABLE 1 | Changes in the MAS, AROM, and FMA scores measured before injection and at 1, 2, 4, 12 weeks after BTX-A injection (mean ± standard
deviation).
After injection (n = 23)
Items Before injection (n = 23) Week 1 Week 2 Week 4 Week 12
MAS (score)
Wrist flexor 3.0 ± 0.6 2.2 ± 0.4 (p < 0.02∗) 1.1 ± 0.3 (p < 0.02∗) 1.3 ± 0.5 (p < 0.02∗) 1.4 ± 0.5 (p < 0.02∗)
Fingers flexor 3.1 ± 0.3 2.4 ± 0.6 (p < 0.02∗) 1.4 ± 0.5 (p < 0.02∗) 1.2 ± 0.4 (p < 0.02∗) 1.3 ± 0.6 (p < 0.02∗)
AROM (degree)
Wrist extensor 2.5 ± 1.9 2.8 ± 1.9 (p = 0.29) 7.0 ± 1.7 (p < 0.02∗) 11.0 ± 1.9 (p < 0.02∗) 16.0 ± 2.6 (p < 0.02∗)
Fingers extensor 3.1 ± 2.1 3.5 ± 2.0 (p = 0.54) 6.6 ± 2.3 (p = 0.002∗) 9.8 ± 2.5 (p < 0.02∗) 13.0 ± 2.9 (p < 0.02∗)
FMA (score)
Wrist-hand 8.8 ± 2.0 9.3 ± 2.1 (p = 0.94) 10.3 ± 2.5 (p = 0.002∗) 13.1 ± 2.4 (p < 0.02∗) 15.4 ± 2.7 (p < 0.02∗)
Abbreviations: MAS, modified Ashworth scale; AROM, active range of motion; FMA, Fugl-Meyer assessment scale; BTX-A, botulinum toxin type A. All p values were
adjusted with Bonferroni Correction (∗20). ∗Statistically significant difference (p ≤ 0.05) in comparison with before injection.
improvements (p < 0.02) from 2 to 12 weeks after the BTX-A
injection.
FMA Assessment
Compared with the baseline FMA results of the wrists and hands
(8.8± 2.0), the FMA scores at 2, 4 and 12 weeks after the injection
were significantly improved (10.3 ± 2.5, 13.1 ± 2.4, and 15.4 ±
2.7, respectively; p < 0.02), whereas the FMA score at 1 week
(9.3 ± 2.1) remained unchanged from the baseline (p = 0.94;
Table 1). Similar to the results of the AROM assessment, the
FMA scores that present motor function of the wrist and hand
maintained significant improvements from 2 weeks to 12 weeks
after the BTX-A injection (p< 0.02).
Discussion
BTX-A as a chemodenervating drug with reversible clinical
effects, offers the possibility to paralyze muscles that contribute
to spastic deformities. The BTX-A dose and correct identification
of the spastic muscles are important factors influencing the
treatment outcome. Chin et al. (2005) injected BTX-A with
the aid of palpation of the target muscles to reduce limb
spasticity in 226 children with cerebral palsy. They concluded
that the accuracy of MNP was acceptable only for the
gastrocnemius and soleus muscles (75%), whereas it was
unacceptable for the forearm and hand muscles (13–35%).
Schroeder et al. (2006) reviewed different injection techniques
of BTX-A and suggested that US-guidance could be a reliable
localization technique, by which the typical patterns of the
target muscle could be recognized in a short period of time
without causing pain. Therefore, sonographic imaging may
potentially be a useful approach for guiding BTX-A injection
into correction locations/muscles for treating adult patients with
spasticity.
US guidance allows identification of the target muscles and
verification of the position of the needle tip in the designated
muscle mass. In addition, US helps identify blood vessels and
nerves, and may help guide the needle to stay away from those
structures. It has been suggested that US could help avoid
BTX-A administration into the blood vessels and nerves, owing
to improved injection accuracy (Henzel et al., 2010). There is
little doubt that using US can help make BTX-A injections safer
and more accurate.
The current study performed US-guided BTX-A injection
to treat wrist and finger spasticity in post stroke patients in
conjunction with rehabilitation intervention. Our target muscles
for the injection included the FDP muscle of the forearm and
due to the depth of this muscle, it is often difficult to determine
the injection spot and depth. With the use of US guidance, the
FDP was quickly identified and the injecting needle was inserted
to the correct location within the muscle relatively easily. This
outcome suggests that deep, small, or superficial muscles can
all be clearly displayed upon the sonographic images to guide
the injection. Without the guidance, it would be challenging to
accurately deposit the drug in the deep musculature.
US-guided BTX-A injection is useful for decreasing spastic
muscle tone in stroke patients. A previous study (Picelli
et al., 2012) concluded that the US-guided injection into
the gastrocnemius muscle could improve functional clinical
outcomes in adults with spastic equinus after stroke. In another
study by the same research group (Picelli et al., 2014), the authors
demonstrated that the MAS scores of the wrist and fingers
improved 4 weeks after US-guided injection in patients post
stroke.
The MAS is often used to assess muscle spasticity level in
clinical studies. Higher scores indicate more severe spasticity
and lower scores mean less spasticity. In addition, the AROM,
PROM and FMA represent common assessment items used for
evaluating active movement and functional status. In the study
by Picelli et al. (2014) on upper limb spasticity, only theMAS and
PROMwere used to assess the therapy outcomes after US-guided
BTX-A injection but no information was provided regarding the
active and functional activities of the patients. In our study, the
AROM and FMA were included in the outcome assessments, in
addition to the MAS assessment of spasticity, thereby allowing
the improvement in patients’ active motor activities to be
assessed after BTX-A injection. Indeed, the results from this
study showed that the MAS, AROM, and FMA measures all
improved in the patients up to 12 weeks after US-guided BTX-
A injection. As opposed to the AROM and FMA data that did
not improve until 2 weeks after the injection, the MAS scores of
the wrist and finger flexors were obviously decreased only 1 week
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after the injection. In other words, the earliest benefit after US-
guided BTX-A injection was seen on the muscle tone. The MAS
score of the wrist flexors reduced further at 2 weeks, but increased
slightly at 4 and 12 weeks compared to the value at 2 weeks.
Similarly, the MAS score of the finger flexors decreased at each
assessment after injection with the largest change in the observed
at 4 weeks. The MAS measure indicated that reduced spasticity
was maintained at 12 weeks after US-guided BTX-A injection.
Moreover, both the AROM of the wrist and finger extensors
and the FMA scores improved 2 weeks after US-guided BTX-A
injection and the improvement was maintained throughout the
rest of the 12 weeks follow-up.
BTX-A is effective for decreasing muscle spasticity.
Rehabilitation exercises after the injection are essential for
motor function improvement. Henzel et al. (2010) performed
a double-blind randomized trial aimed at investigating the
effects of treating the upper limbs spasticity in 24 post-stroke
patients using BTX-A injection with and without ES therapy.
The authors found that combined with ES therapy, the BTX-A
injection induced significant improvements in the spastic muscle
tone, movement range of the joint and daily living activities
of the patients. The wrist and finger flexor muscles could be
stretched more easily with an increase in AROM. Through
comprehensive conventional rehabilitation exercises after the
injection, including strengthening exercises of the agonistic
and antagonistic muscles, coordination exercises of multiple
joints, and functional ES of target muscles, spasticity and
motor function can be more remarkably improved than BTX-A
injection not accompanied rehabilitative exercises. Moreover,
in the study led by Woldag and Hummelsheim (2003), the
authors found that the AROM increased and MAS decreased
significantly in the wrist flexors at 4, 8 and 12 weeks after
BTX-A injection in stroke patients. Accordingly, we suggest
that US-guided BTX-A injection combined with rehabilitation
exercises can lead to functional benefits for stroke patient with
wrist and finger flexor spasticity but BTX-A injection alone may
not achieve such beneficial results.
It is well known that the effect of BTX-A injection varies
over time. In the study by Picelli et al. (2014) on upper limb
spasticity, clinical outcomes were only assessed at one time-
point (4 weeks) after the injection, and therefore, the effect of
time on the outcomes could not be determined. In this study,
the follow-up time points were 1, 2, 4 and 12 weeks after
injections and the results showed that the wrist and finger flexor
spasticity of the patients subsided only 1 week after US-guided
injection. At the other follow-up time points (2, 4 and 12 weeks),
the changes were also significant but varied in amplitude. A
previous study found that decreased MAS scores of the wrist and
fingers were obvious 4 weeks after BTX-A injection (Woldag and
Hummelsheim, 2003), which is similar to the outcome found
in our study. The patients in that study were assessed at 4, 8
and 12 weeks after BTX-A injection, and the authors reported
that the MAS, PROM, and AROM scores were all improved
during the follow-up (Woldag and Hummelsheim, 2003). In
the present study, similar results were observed in terms of the
MAS and AROM measures of the wrist and fingers. To compare
with previous studies (Woldag and Hummelsheim, 2003; Picelli
et al., 2014) and to allow for a complete observation of spasticity
therapy outcomes, we observed the outcomes not only in longer
terms (4–12 weeks), but also in shorter terms (1–2 weeks). We
consider that data observed at more time points are helpful to
understand the spasticity tendency after BTX-A injection and
to potentially create a proper therapy plan for patients with
spasticity. However, it is still unclear whether the spasticity
decreases more quickly by US-guided injection compared with
other guidance methods.
Finally, this study used sonographic imaging online to guide
BTX-A injection to treat post-stroke spasticity and satisfying
outcomes were achieved. The US guidance provides real-time
visual images of the needle placement and anatomic information
of the target muscles. US-guided BTX-A injection combined
rehabilitation exercises help decrease muscle spasticity and
further improve upper limb motor function at short and
longer follow-up time points. By demonstrating favorable results
of combining US-guided BTX-A injection with conventional
rehabilitation interventions with clinical outcome measures
assessed at multiple follow-up time points, the current study
provides new information relevant to efficacies of US-guided
BTX-A injection and rehabilitation on treating muscle spasticity
and improving muscular function.
This study, however, has limitations that include primarily the
lack of a control group withMNP injection without US guidance.
Very few patients expressed interest in MNP, and few patients
wanted to accept US-guided injection without rehabilitation
intervention in our hospital. These conditions made it difficult
to establish a MNP + rehabilitation group and/or US-guided
BTX-A injection without rehabilitation group. However, even
without a control group we believe our results are valid based on
findings reported by previous studies that have shownUS-guided
injection was more effective in improving outcome measures
than MNP injection in stroke patients with lower and upper
limb muscle spasticity (Picelli et al., 2012, 2014). Hesse et al.
(1998) compared the clinical outcomes between interventions
of BTX injection + ES and BTX injection alone in stroke
patients with spasticity. The BTX + ES group had more spasticity
reduction and better limb positioning at rest. Other research
groups demonstrated BTX-A injection combining rehabilitation
improved functional activities and decreased muscle spasticity
in a small number of stroke survivors with wrist and finger
spasticity (Woldag and Hummelsheim, 2003; Cardoso et al.,
2007). In future studies on using US-guided BTX-A injection
for treating spasticity of both upper and lower limbs in post-
stroke patients, we would recruit more subjects by cooperation
with other health care centers and launch more comprehensive
clinical studies on whether US-guided injection has a better
treatment result than other injection techniques and whether US-
guided injection combined with a rehabilitation program is more
effective in improving spasticity and motor function than the
US-guided injection alone. We would also like to determine if
spastic muscles at certain joints are more suitable for US-guided
injection than others.
In conclusion, the results of this study suggest that the use
of US can help accurately locate the target muscle and region
within the muscle for needle placement, and that US-guided
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BTX-A injection combined with rehabilitation exercises can not
only decrease spasticity of the wrist and finger flexor muscles at
various times following the injection and rehabilitation, but can
the approach also significantly improve motor function of the
wrist and fingers in patients during post-stroke rehabilitation.
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